CJC/IPA Protocol vs Tesamorelin
Well Studied vs FDA Approved
monitor Mechanism-based · 47% Both CJC/IPA Protocol and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
CJC/IPA Protocol Tesamorelin
Weight N/A 5,135.9 Da
Half-life — 26-38 minutes
Chain N/A 44 amino acids
Type Peptide combination (GHRH analog + GHS) GHRH analog
Key Benefits
CJC/IPA Protocol
01 Sustained GH elevation (6-8 days from CJC-1295)
02 Selective pulsatile release without cortisol suppression
03 Complementary dual-pathway optimization
04 Preservation of natural GH rhythm
05 Enhanced muscle protein synthesis and recovery
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
CJC/IPA Protocol
200-300mcg of each peptide (CJC-1295 and Ipamorelin) / Once daily, preferably in the evening
General Health Optimization 200mcg each (0.2mL if 1mg/mL) Once daily
Performance Enhancement 250mcg each (0.25mL if 1mg/mL) Once daily
Recovery Optimization 300mcg each (0.3mL if 1mg/mL) Once daily
Conservative Approach 150mcg each (0.15mL if 1mg/mL) 5 days per week
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
CJC/IPA Protocol
Water retention and joint swelling
Carpal tunnel syndrome (numbness/tingling)
Mild blood glucose elevation
Injection site irritation with improper rotation
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Cancer history or active malignancy
Severe diabetes requiring tight glucose control
Carpal tunnel syndrome or nerve compression disorders
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
CJC/IPA Protocol Tesamorelin
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest June 2024 June 2025
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.